OKYO
OKYO Pharma Limited · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website okyopharma.com
- Employees(FY) 8
- ISIN GG00BMFG5F62
Performance
+0.66%
1W
+4.83%
1M
+7.8%
3M
-10.06%
6M
-14.12%
YTD
-12.64%
1Y
Profile
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.
Technical Analysis of OKYO 2024-05-10
Overview:
In analyzing the technical indicators for OKYO stock over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions to guide inves...
Recent News & Updates
- 2023-05-08 20:45
- 2023-05-04 01:22
- 2023-05-02 14:00
- 2023-05-01 14:00
- 2023-04-24 14:00
- 2023-04-17 22:00
Page 2 of 2
previousnext